Related Experiment Videos
[Monoclonal gammopathy and platelet function (author's transl)]
Wiener Klinische Wochenschrift
|November 23, 1979
Summary
Patients with monoclonal gammopathy, including multiple myeloma, exhibit impaired platelet function. This primary hemostasis disorder contributes to bleeding risks in these individuals.
Area of Science:
- Hematology
- Oncology
- Internal Medicine
Context:
- Monoclonal gammopathies, such as multiple myeloma and Waldenström's syndrome, are plasma cell disorders.
- Bleeding diathesis is a recognized complication in patients with these conditions.
- Primary hemostasis involves platelet aggregation and retention, crucial for blood clotting.
Purpose:
- To investigate primary hemostasis parameters in patients with monoclonal gammopathy.
- To determine the relationship between hemostatic defects and protein abnormalities.
- To identify the primary cause of bleeding tendencies in monoclonal gammopathy.
Summary:
- A study of 20 patients with monoclonal gammopathy (17 multiple myeloma, 3 Waldenström's syndrome) revealed decreased platelet aggregation and retention, and prolonged bleeding time in 25% of cases.
- Platelet function tests showed impaired responses to ADP and collagen, with increased reversible platelet aggregates observed.
- No correlation was found between primary hemostasis parameters and protein analysis, suggesting a distinct mechanism.
Impact:
- Identifies a disturbed primary hemostasis mechanism as the main factor responsible for bleeding diathesis in monoclonal gammopathy.
- Highlights the importance of assessing platelet function in managing bleeding risks for these patients.
- Provides insights into the pathophysiology of bleeding complications in plasma cell disorders.